Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera. The only curative option is allogeneic hematopoietic cell transplantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients. Unfortunately the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded from such an approach. Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short. Complications such as graft-versus-host disease remain the major barrier to greater success. At present this modality is generally restricted to younger patients with intermediate- to high-risk disease. We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis. We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.

Original languageEnglish (US)
Pages (from-to)34-42
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Primary Myelofibrosis
Cell Transplantation
Homologous Transplantation
Essential Thrombocythemia
Myeloproliferative Disorders
Polycythemia Vera
Graft vs Host Disease
Comorbidity
Tissue Donors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{fb35c165a0c44c6d8a92875ffa318e91,
title = "Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia",
abstract = "Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera. The only curative option is allogeneic hematopoietic cell transplantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50{\%} of eligible patients. Unfortunately the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded from such an approach. Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short. Complications such as graft-versus-host disease remain the major barrier to greater success. At present this modality is generally restricted to younger patients with intermediate- to high-risk disease. We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis. We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.",
author = "William Hogan and Litzow, {Mark R} and Ayalew Tefferi",
year = "2007",
month = "1",
doi = "10.1007/s11899-007-0005-3",
language = "English (US)",
volume = "2",
pages = "34--42",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia

AU - Hogan, William

AU - Litzow, Mark R

AU - Tefferi, Ayalew

PY - 2007/1

Y1 - 2007/1

N2 - Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera. The only curative option is allogeneic hematopoietic cell transplantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients. Unfortunately the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded from such an approach. Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short. Complications such as graft-versus-host disease remain the major barrier to greater success. At present this modality is generally restricted to younger patients with intermediate- to high-risk disease. We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis. We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.

AB - Myelofibrosis with myeloid metaplasia is a clonal disorder resulting from proliferation of aberrant hematopoietic progenitors. It can occur either de novo or secondary to an antecedent chronic myeloid disorder such as essential thrombocythemia or polycythemia vera. The only curative option is allogeneic hematopoietic cell transplantation, which can result in durable donor engraftment and regression of myelofibrosis in approximately 50% of eligible patients. Unfortunately the median age at presentation is 65 years and many patients have serious comorbidities, so the vast majority of patients are excluded from such an approach. Reduced-intensity conditioning regimens have been shown to result in successful engraftment and resolution of myelofibrosis with less toxicity, although follow-up remains relatively short. Complications such as graft-versus-host disease remain the major barrier to greater success. At present this modality is generally restricted to younger patients with intermediate- to high-risk disease. We provide a current algorithm for incorporating allogeneic transplantation into the management of patients with myelofibrosis. We are hopeful that recent advances in allogeneic transplantation, combined with progress in understanding the molecular pathobiology of chronic myeloproliferative disorders, will lead in the near future to a further refinement of prognostic determinants, new molecular targets to exploit, and therefore a dynamic evolution of the indications for allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=34250718002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250718002&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0005-3

DO - 10.1007/s11899-007-0005-3

M3 - Article

C2 - 20425386

AN - SCOPUS:34250718002

VL - 2

SP - 34

EP - 42

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -